CN Patent

CN113769097A — Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2021-12-10 · 4y expired

What this patent protects

EGFR/HER2抑制剂联合嘧啶类抗代谢药物的用途，具体涉及一种EGFR/HER2受体酪氨酸激酶抑制剂联合嘧啶类抗代谢药物在制备治疗癌症的药物中的用途。

USPTO Abstract

EGFR/HER2抑制剂联合嘧啶类抗代谢药物的用途，具体涉及一种EGFR/HER2受体酪氨酸激酶抑制剂联合嘧啶类抗代谢药物在制备治疗癌症的药物中的用途。

Drugs covered by this patent

neratinib-maleate (NERATINIB MALEATE)

Patent Metadata

Patent number: CN113769097A
Jurisdiction: CN
Classification: —
Expires: 2021-12-10
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Hengrui Medicine Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.